Our 2018 Drug Report

In 2018, more than 50% of our clients experienced a negative overall drug trend. Our trend report highlights our industry-leading results in managing specialty and chronic conditions—two main drivers of escalating drug costs for pharmacy plans.

0.3% Overall Trend

Our clinical philosophy is centered on helping patients choose and stay adherent to the most cost-effective medications and avoiding unnecessary escalation to higher cost therapy.

5.7%

Specialty Trend

Our success engaging with physicians and patients helped drive our industry-leading specialty pharmacy trend. Our engagement strategy is anchored by WellConnect, a personalized messaging tool.

2.5%

WellManaged – Diabetes Program

One of the most prevalent chronic conditions, members in our WellManaged Diabetes program experienced a 2.5% trend. Clients not using our specialized program experienced a 13% trend.

-13.7%

WellManaged – Pain Inflammation

Clients in our WellManaged Opioids and Hyperinflationary Drug Programs experienced substantial utilization and unit cost decreases in the Pain Inflammation category.


Please fill out the form to access the full trend report.



Interested in our Trend Report Webinar?

The WellDyne clinical team provides detailed insights into pharmacy trend drivers in 2018, and unpacks how more than 50% of our clients experienced a negative overall drug trend.

Change starts now.

Let’s work together to make benefits better. Ready to learn more? Contact our team to start the conversation.

Contact Us